➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
Moodys
McKesson
Baxter
Boehringer Ingelheim

Last Updated: May 10, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Cimetidine Hydrochloride In Sodium Chloride 0.9% In Plastic Container

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002092 A Study to Evaluate the Effect of Cimetidine on CD4 Lymphocyte Counts in HIV Infection Completed Community Research Initiative of New England N/A 1969-12-31 To determine the change in CD4 count after 4 and 8 weeks in HIV-infected patients treated with cimetidine compared to placebo. To observe time-associated trends at weeks 4, 8, 12, and 16 in the change of CD4 counts for patients taking cimetidine for the full 16 weeks. To establish a safety record for cimetidine use in HIV-positive patients.
NCT00002733 Biological Therapy in Treating Patients With Metastatic Cancer Completed Hoag Memorial Hospital Presbyterian Phase 2 1996-01-01 RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining different types of biological therapies, including interferon alfa, interleukin-2, and tumor infiltrating lymphocytes, may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of biological therapies, including interferon alfa, interleukin-2, and tumor infiltrating lymphocytes, in treating patients with metastatic cancer.
NCT00038402 Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer Completed Genentech, Inc. Phase 3 2001-04-01 The purpose of this study is to evaluate the addition of Herceptin to standard chemotherapy treatment of patients newly diagnosed with operable breast cancer. Other objectives: 1) to evaluate the potential of this therapy to reduce the size of the tumor and increase the possibility of breast conservative surgery, 2) evaluate the ability of this regimen to prevent recurrence of breast cancer and impact on survival, 3) determine side effect profile with the addition of Herceptin, and 4) evaluate significance of HER2 expression by two different methods.
NCT00038402 Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer Completed M.D. Anderson Cancer Center Phase 3 2001-04-01 The purpose of this study is to evaluate the addition of Herceptin to standard chemotherapy treatment of patients newly diagnosed with operable breast cancer. Other objectives: 1) to evaluate the potential of this therapy to reduce the size of the tumor and increase the possibility of breast conservative surgery, 2) evaluate the ability of this regimen to prevent recurrence of breast cancer and impact on survival, 3) determine side effect profile with the addition of Herceptin, and 4) evaluate significance of HER2 expression by two different methods.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Cimetidine Hydrochloride In Sodium Chloride 0.9% In Plastic Container

Condition Name

Condition Name for Cimetidine Hydrochloride In Sodium Chloride 0.9% In Plastic Container
Intervention Trials
Healthy 5
Breast Cancer 3
Gastric Cancer 2
COPD 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Cimetidine Hydrochloride In Sodium Chloride 0.9% In Plastic Container
Intervention Trials
Breast Neoplasms 4
Carcinoma 4
Hemorrhage 2
Stomach Neoplasms 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Cimetidine Hydrochloride In Sodium Chloride 0.9% In Plastic Container

Trials by Country

Trials by Country for Cimetidine Hydrochloride In Sodium Chloride 0.9% In Plastic Container
Location Trials
United States 81
China 5
Germany 4
Canada 2
France 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Cimetidine Hydrochloride In Sodium Chloride 0.9% In Plastic Container
Location Trials
Texas 14
Florida 4
Pennsylvania 4
Illinois 4
Minnesota 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Cimetidine Hydrochloride In Sodium Chloride 0.9% In Plastic Container

Clinical Trial Phase

Clinical Trial Phase for Cimetidine Hydrochloride In Sodium Chloride 0.9% In Plastic Container
Clinical Trial Phase Trials
Phase 4 7
Phase 3 10
Phase 2/Phase 3 1
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Cimetidine Hydrochloride In Sodium Chloride 0.9% In Plastic Container
Clinical Trial Phase Trials
Completed 29
Active, not recruiting 6
Unknown status 6
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Cimetidine Hydrochloride In Sodium Chloride 0.9% In Plastic Container

Sponsor Name

Sponsor Name for Cimetidine Hydrochloride In Sodium Chloride 0.9% In Plastic Container
Sponsor Trials
M.D. Anderson Cancer Center 11
Genentech, Inc. 5
Boehringer Ingelheim 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Cimetidine Hydrochloride In Sodium Chloride 0.9% In Plastic Container
Sponsor Trials
Other 50
Industry 32
U.S. Fed 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Baxter
Colorcon
Dow
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.